Dapagliflozin effect on cardiopulmonary, echocardiographic function, biomarkers and NYHA class in HFrEF patients
Anno:
2024
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are currently a standard therapy for patients with heart failure with reduced ejection fraction (HFrEF). This study aims to assess the effects of Dapagliflozin on exercise capacity, cardiac biomarkers, fluid retention, renal and pulmonary function. Methods: We prospectively enrolled stable HFrEF outpatients (left ventricular…